With headquarters located in the USA in the greater Philadelphia area, SSPCC specializes in partnering and facilitating the conduct of all aspects of pharmacology and toxicology required for preclinical drug development, from Discovery to the Monitoring of Preclinical Trials to the Report Generation and Development Team Activities to the Management behind it all. Companies can then meet their schedules and workloads, take advantage of the latest technologies, and adhere to GLP and regulatory guidelines.
Founder and Principal, Caroline Bell, Ph.D.
Recognizing an unmet need in the rapidly growing field of Safety Pharmacology Dr. Caroline Bell founded SSPCC, Inc in 2001. Because of the cyclical nature of preclinical drug development, the rapid growth and changes in scientific and regulatory requirements and a shortage of individuals trained in this specialty, companies found themselves behind schedule, overworked, understaffed, and sometimes unable to meet the requirements of the Safety Pharmacology ICH S7A Guidelines , ICH S7B guidelines in a timely and efficient manner. Even with the use of the growing numbers of CROs, the contract management and oversight of the work required additional resource and expertise.
Dr. Bell was trained in classical Pharmacology in the UK at Bath University, obtained her PhD at New York Medical College and did her post-doctoral work at Cornell University Medical College. She has over 20 years experience as a pharmacologist, preclinical safety assessment scientist and manager/director in the academic and global pharmaceutical arenas, She is currently on the board of directors for the Safety Pharmacology Society.Caroline Bell Resume (64.75 kB)